Table 3.
The impact of intersectoral costs on the total costs of STIs and HIV
| Authors | Healthcare costs | Patient/family costs | Productivity (labour) costs | Total intersectoral costs | Total costs (healthcare and intersectoral) | Proportion of intersectoral costs on the total cost (%) |
|---|---|---|---|---|---|---|
|
Kuhlmann et al. (HIV) |
Total healthcare costs: 22,457 €/year [2009-2011] per patient |
Patient out-of-pocket costs: 216 €/year per patient |
1,890 €/year per patient | 2,106 €/year per patient | 24,563 €/year per patient | 9 % |
| [US$ 2021: 29.437] | [US$ 2021: 283] | [US$ 2021: 2,474] | [US$ 2021: 2,765] | [US$ 2021:32.200] | ||
|
Lopez-Bastida et al. (HIV) |
Total healthcare costs (asymptomatic HIV): 7,148 €/year [2003] per patient |
NA |
Asymptomatic HIV: 3,383 €/year per patient |
3,383 €/year per patient |
Asymptomatic HIV: 10,531 €/year per patient |
“Productivity losses for people living with HIV to range between 3,383€ (asymptomatic HIV) and 5,981€ (symptomatic HIV), representing a range of 32-41 % of the total costs.” [as reported in the original study] |
| [US$ 2021: 10,611] | [US$ 2021: 5,023] | [US$ 2021: 5,023] | [US$ 2021: 15,635] | |||
|
Total healthcare costs (symptomatic HIV): 8,508 €/year per patient |
Symptomatic HIV: 5,981 €/year per patient |
5,981 €/year per patient |
Symptomatic HIV: 14,489 €/year per patient |
|||
| [US$ 2021: 12,632] | [US$ 2021: 8,879] | [US$ 2021: 8,879] | [US$ 2021: 21,512] | |||
|
Mostardt et al. (HIV) |
Total healthcare costs (SHI): 19,103 €/year [2008] per patient* | NA |
Disability-related productivity loss (labour): 489 €/year per patient |
489 €/year per patient | 23,298 €/year per patient |
“9 % of total cost from the societal perspective could be attributed to indirect costs [disability, productivity loss].” [as reported in the original study] |
| [US$ 2021: 25,865] | [US$ 2021: 662] | [US$ 2021: 662] | [US$ 2021: 31,542] | |||
|
Long-term productivity loss (labour): 1,294 €/year per patient |
1,294 €/year per patient | |||||
| [US$ 2021: 1,752] | [US$ 2021: 1,752] | |||||
|
Partial productivity loss (labour): 337 €/year per patient |
337 €/year per patient | |||||
| [US$ 2021: 456] | [US$ 2021: 456] | |||||
|
Owusu-Edusei et al. (non-viral) |
NA | NA |
Average productivity costs (labour) per case/2001-2005 [2011 values]: US$ 262 for chlamydia [US$ 2021: 312] |
US$ 262 for chlamydia per case | NA | NA |
|
US$ 197 for gonorrhoea [US$ 2021: 234] |
US$ 197 for gonorrhoea per case | |||||
|
US$ 419 for syphilis [US$ 2021: 498] |
US$ 419 for syphilis per case | |||||
|
US$ 289 for trichomoniasis [US$ 2021: 344] |
US$ 289 for trichomoniasis per case | |||||
|
Shon et al. (Hepatitis A, B, C) |
NA | NA | NA | NA |
Hepatitis A: US$ 45.7 million/2008-2011 [US$ 2021: 54,3 million] |
“[…] with indirect costs [opportunity costs lost as a result of medical care, or premature death and caregiver costs] accounting for the remaining 65 % during the observation period [2008-2011].” (Hepatitis A) |
|
Hepatitis B: US$ 607.8 million/2008-2011 [US$ 2021: 722.8 million] |
“Indirect costs were estimated to be approximately 53.4 % of this total over the same period [2008-2011]” (Hepatitis B) |
|||||
|
Hepatitis C: US$ 90.7 million/2008-2011 [US$ 2021: 107.8 million] |
“[…] with indirect costs accounting for the remaining 42.0 % in 2011.” (Hepatitis C) [as reported in the original study] |
|||||
|
Yang et al. (Hepatitis B) |
Direct costs (direct formal medical costs, informal medical costs, and non-medical costs): 474,642 million KRW/year [2005] [or 0.474,642 trillion]** |
NA [refer to the column on the right] |
Indirect costs (time costs, caregiver costs, productivity losses): 1.463 trillion KRW/year incurred by HBV-related disease patients |
1.463 trillion KRW/year incurred by HBV-related disease patients | 1.937 trillion KRW/year | 75,5 % |
| [US$ 2021: 558,639,140] | [US$ 2021: 1,721,832,880] | [US$ 2021: 1,721,832,880] | [US$ 2021: 2,279,692,610] |
KRW Korean Won, NA Not applicable, SHI Statutory health insurance, US United States Dollar
*In the original study, patient travel costs and costs for homecare provided by family/friends were included in the calculation of healthcare costs.
**In the original study, patient costs (patient resource consumption outside the health care system: dietary supplements, over the counter drugs, other treatment-related services) and transportation costs were included in the calculation of direct costs (healthcare costs).
The reported costs were converted to US Dollar and the year 2021, adjusting the values by inflation.